Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF

PHASE4UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Female InfertilityPoor Responder
Interventions
DRUG

Long acting FSH and GnRH antagonist

Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.

DRUG

Daily FSH and GnRH antagonist

Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.

DRUG

Triptorelin and recombinant FSH

Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.

Trial Locations (1)

00197

RECRUITING

Bioroma, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bioroma

OTHER